Compare DexCom, Inc. (DXCM) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vanguard High Dividend Yield ETF — how do they compare? DexCom, Inc. trades at $78.55 (market cap $28.06B), while Vanguard High Dividend Yield ETF trades at $160.95. The key difference: Vanguard High Dividend Yield ETF is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | VYM | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | — |
52-Week High | $89.53 | $161.17 |
52-Week Low | $54.84 | $132.90 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Vanguard High Dividend Yield ETF (VYM) trades at $160.62, showing modest daily gains with bullish technical signals from moving averages. The ETF maintains broad diversification across 618 U.S. large-cap dividend payers with an ultra-low 0.04% expense ratio. Recent financial media coverage highlights VYM's role in retirement income strategies, comparing it favorably to peers like SCHD and HDV for its balance of yield and cost efficiency.
VYM presents a core holding for income-focused investors seeking diversified exposure to high-yield U.S. equities. The primary opportunity lies in its consistent dividend distributions and low-cost structure, while risks include interest rate sensitivity and potential underperformance during growth-dominated market cycles. Current technical positioning suggests near-term support around $159-160 with resistance at $161.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
